Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-22T06:47:31.770Z Has data issue: false hasContentIssue false
  • English
  • Français

Depot Injections and Tardive Dyskinesia

Published online by Cambridge University Press:  29 January 2018

Alan C. Gibson
Alan C. Gibson*
Affiliation:
East Dorset Health Care District (St Ann's Hospital, Canford Cliffs, Poole, Dorset); Hon. Lecturer, University of Southampton
Get access Rights & Permissions [Opens in a new window]

Summary

A prospective study was undertaken on 374 out-patients receiving depot fluphenazine or depot flupenthixol to determine the incidence of tardive dyskinesia. In three years the percentage showing the bucco-linguo-masticatory syndrome rose from 8 per cent to 22 per cent, though patients had received various neuroleptics for a mean of 13 years previously. Fluphenazine and flupenthixol were equally involved though 75 per cent of affected patients had the condition in mild degree. Six additional cases of generalized chorea were all receiving flupenthixol. Reduction of dose or the substitution of pimozide produced marked improvement, but results suggest that it is unlikely that this will be permanent. Substitution of depot fluspirilene also produced favourable results. Careful monitoring, minimal neuroleptic dosage, and periods of neuroleptic abstinence are recommended.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 133 , Issue 4 , October 1978 , pp. 361 - 365
Copyright
Copyright © Royal College of Psychiatrists, 1978 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adamson, L., Curry, S. H., Bridges, P. K., Firestone, A. F., Lavin, N. I., Lewis, D. M., Watson, R. D., Xavier, C. M. & Anderson, J. A. (1973) Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral chlorpromazine. Diseases of the Nervous System, 34, 181–91.Google Scholar
Baldessarini, R. J., Marsden, C. D. & Tarsy, D. (1975) Spontaneous and drug-induced movement disorders in psychotic patients. In Psychiatric Aspects of Neurologic Disease. (Eds. Benson, D. F. and Blumer, D.) Grune and Stratton Inc. Google Scholar
Brandon, S., McClelland, M. A. & Protheroe, C. (1971) A study of facial dyskinesia in a mental hospital population. British Journal of Psychiatry, 118, 171–84.Google Scholar
Carlsson, A. (1970) Biochemical implications of dopa induced action on the central nervous system with particular reference to abnormal movements. In L dopa and Parkinsonism, pp 205–12. (Eds. Barbeau, A. and McDowell, F. H.) Philadelphia: F. A. Davis and Co.Google Scholar
Costall, B. & Naylor, R. J. (1977) Behavioural characterization of neuroleptic properties—read at Symposium on schizophrenia and dopamine at Royal Society of Medicine, London, October 21.Google Scholar
Crane, G. E. (1968) Tardive dyskinesias in patients treated with major neuroleptics—a review of the literature. American Journal of Psychiatry, 124 (February supplement), 40–8.Google Scholar
Crane, G. E. (1970) High doses of trifluperazine and tardive dyskinesia. Archives of Neurology, 33, 176–80.Google Scholar
Crane, G. E. (1973) Persistent dyskinesia. British Journal of Psychiatry, 122, 395–401.CrossRefGoogle ScholarPubMed
Degwitz, R. (1969) Extrapyramidal motor disorders following long term treatment with neuroleptic drugs. In Psychotropic Drugs and Dysfunctions of the Basal Ganglia, pp 22–32 (Eds. Crane, G. E. and Gardner, R. Jr.) Public Health Publication (America).Google Scholar
Dynes, J. B. (1970) Oral dyskinesias, occurrence and treatment. Diseases of the Nervous System, 31, 854–9.Google Scholar
Eckmann, F. (1968) Zur Problematik von Dauerschaden nach neuroleptischer Langzeitbehandlung. Therapie der Gegenwart, 107, 316–23.Google Scholar
Fann, W. E., Davis, J. M. & Janowsky, D. S. (1972) The prevalence of tardive dyskinesia in mental hospital patients. Diseases of the Nervous System, 33, 182–6.Google Scholar
Fann, W. E. & Lake, R. (1974) On the coexistence of parkinsonism and tardive dyskinesia. Diseases of the Nervous System, 35, 324–6.Google ScholarPubMed
Gerlach, J. (1977) Relationship with tardive dyskinesia, L dopa induced hyperkinesia and Parkinsonism. Psychopharmacology, 51, 259–63.Google Scholar
Jus, A., Pineau, R., Lachance, R., Pelchet, G., Jus, K., Pires, P. & Villeneuve, R. (1976) Epidemiology of tardive dyskinesia, Part I. Diseases of the Nervous System, 37, 210–13 and 257–61.Google Scholar
Kennedy, P. F., Herson, H. I. & McGuire, R. J. (1971) Extrapyramidal disorders after prolonged phenothiazine therapy. British Journal of Psychiatry, 118, 509–13.Google Scholar
Kiloh, L. G., Smith, J. S. & Williams, S. E. (1973) Anti-parkinson drugs as causal agents in tardive dyskinesia. Medical Journal of Australia, 2, 591–3.Google Scholar
Klawans, H. L., Haki, M. M. & Shenker, D. (1970) The theoretical implications of the use of L-dopa in parkinsonism. Acta Neurologica Scandinavia, 46, 409–41.Google Scholar
Klawans, H. L. (1973) The pharmacology of tardive dyskinesia. American Journal of Psychiatry, 130, 82–6.Google Scholar
Marriett, P. F. (1975) Potentiation of tardive dyskinesia. Possible drug interaction. British Medical Journal, ii, 139.Google Scholar
McLennan, H. & York, D. H. (1967) The action of dopamine on neurones of the caudate nucleus. Journal of Physiology, 189, 393–402.Google Scholar
Roxburgh, P. A. (1970) Treatment of phenothiazine induced oral dyskinesia. British Journal of Psychiatry, 116, 277–80.Google Scholar
Schonecker, M. (1957) Ein eigentümliches Syndrom im oralen Bereich bei Megaphen Applikation. Nervenarzt, 28, 35.Google Scholar
Sigwald, J., Boultier, D. & Courvoisier, S. (1959) Les accidents neurologiques des medications neuroleptiques. Revue Neurologique, 100, 553–95.Google Scholar
Smith, E. B. (1974) Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurologica Scandinavica, 50, 801–11.Google Scholar
Villeneuve, A. & Boszormenyi, Z. (1970) Treatment of drug induced dyskinesias. Lancet, ii, 353–4.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.